Trials / Completed
CompletedNCT02505295
Selenium and Ischemic Stroke Outcome
Evaluation of Selenium Supplementation in Ischemic Stroke Outcome
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Mazandaran University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 20 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
Selenium is a trace element essential to human health.Selenium protection against cellular damage by oxygen radicals is accomplished through selenoproteins. Ischemic stroke is associated with the generation of oxygen free radicals resulting in a condition of oxidative stress. Supplementing stroke patients with antioxidant nutrients may improve survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Selenium | 4 vials selenase stat and 2 vials daily for 5 days |
| DRUG | normal saline | Normal saline infusion like intervention group |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2015-07-22
- Last updated
- 2020-01-27
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT02505295. Inclusion in this directory is not an endorsement.